Discovery of 2-((4-(phenylsulfonyl)piperazin-1-yl)methyl)-1H-indole derivative B9, an anti-inflammatory agent targeting acute and chronic inflammation for the treatment of acute lung injury and diabetic kidney disease.
文献摘要
Inflammatory diseases constitute a critical category of global health burdens. Acute lung injury (ALI) and diabetic kidney disease (DKD) are representative diseases of acute and chronic inflammatory diseases. Suppression of excessive pro-inflammatory cytokine release represents a promising therapeutic strategy. In this study, we designed and synthesized a series of indole-based derivatives to evaluate their anti-inflammatory potential. Biological evaluation in mouse macrophage (RAW264.7/J774A.1) and human monocytic (THP-1) cells identified compound B9 as the most potent inhibitor on the release of cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Mechanistic studies demonstrated that B9 suppressed inflammation by inhibiting the NF-κB/MAPK pathways. In vivo toxicity and tissue distribution study showed B9 having favorable safety profile and high concentrations in lung/kidney. In mouse efficacy studies, B9 exerted potent anti-inflammatory efficacy against lipopolysaccharide (LPS)- and cecal ligation and puncture (CLP)-induced ALI. Moreover, B9 conferred prominent renoprotective effects in both type 1 and type 2 DKD mouse models. However, the pharmacokinetic profile of B9 remains suboptimal, warranting further investigation. These findings identified B9 as a lead structure for further development.